neuromodulators

Bonti Releases Phase 2A Clinical Study Data for its Botulinum Toxin Product

New E serotype E botulinum toxin completes first clinical trial

Bonti, a clinical-stage biotechnology company, has announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours) and short duration of effect (about 4 weeks).

Modulating Expression

Physicians share their techniques for obtaining better longevity and more natural-looking results with botulinum toxins.
Improving longevity and outcomes with neurotoxins

What started as a simple injection to lessen crow’s feet has blossomed into a multibillion dollar market and given rise to today’s medical aesthetics industry. With nearly 30 years of experience and a growing variety of botulinum toxins entering the market, the current focus in neuromodulation is on extending the longevity of results and delivering natural-looking outcomes.